Three patients now treated with NextCells ProTrans stem cells
NextCell Pharma AB ("NXTCL") announces that three type 1 diabetes patients have been treated withProTrans in the ongoing clinical phase I/II trial. Thus, all patients in the low-dose-cohort have nowundergone treatment.The trial performed with NXCTCL's patent-pending ProTrans, is divided into two parts, the first part being a doseescalationphase with 3 + 3 + 3 patients being treated with either a; low, medium or high dose of ProTrans. Nowthat all patients in the low-dose-cohort have been treated and after the 1-month follow-up is completed we canstart inclusion of patients in the